Journal article

Subtype and pathway specific responses to anticancer compounds in breast cancer

Laura M Heiser, Anguraj Sadanandam, Wen-Lin Kuo, Stephen C Benz, Theodore C Goldstein, Sam Ng, William J Gibb, Nicholas J Wang, Safiyyah Ziyad, Frances Tong, Nora Bayani, Zhi Hu, Jessica I Billig, Andrea Dueregger, Sophia Lewis, Lakshmi Jakkula, James E Korkola, Steffen Durinck, Francois Pepin, Yinghui Guan Show all

Proceedings of the National Academy of Sciences of the United States of America | NATL ACAD SCIENCES | Published : 2012

University of Melbourne Researchers

Grants

Awarded by Office of Science, Office of Biological and Environmental Research, of the US Department of Energy


Awarded by National Institutes of Health, National Cancer Institute


Awarded by NHGRI


Awarded by DOD


Awarded by Stand Up to Cancer-American Association for Cancer Research Dream Team Translational Cancer Research


Awarded by SmithKline Beecham Corporation


Awarded by Millennium Pharmaceuticals, Inc.


Awarded by Cytokinetics, Inc.


Awarded by Celgate, Inc.


Awarded by Progen Pharmaceuticals Ltd.


Awarded by NATIONAL CANCER INSTITUTE


Funding Acknowledgements

This work was supported by the Director, Office of Science, Office of Biological and Environmental Research, of the US Department of Energy under Contract DE-AC02-05CH11231; by the National Institutes of Health, National Cancer Institute Grants P50 CA058207 (to J.W.G.); U54 CA112970 (to J.W.G.); NHGRI U24 CA126551 (to P.T.S.), K08CA137153 (to E.A.C.), DOD BC087768 (to A.S.), and by Stand Up to Cancer-American Association for Cancer Research Dream Team Translational Cancer Research Grant SU2C-AACR-DT0409 (to J.W.G.). Additionally, this work was supported by contracts with the following companies: SmithKline Beecham Corporation (LB06002417); Millennium Pharmaceuticals, Inc. (LB09005492); Cytokinetics, Inc. (LB08004488); Celgate, Inc. (LB07003395); and Progen Pharmaceuticals Ltd. (LB08005005).